Anticonvulsants

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	**DD** – Drug-Drug Interaction	**MD** – Maximum Dose Limit	**TD** - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	**DS** Maximum Days' Supply Allowed	**PR** – Enrollment in a Physician-Supervised Program Required	**UN** – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	**DT** – Duration of Therapy Limit	**PU** – Prior Use of Other Medication is Required	**X** – Prescriber Must Have 'X' DEA Number
CL – Additional Clinical Information is Required	**DX** – Diagnosis Code Requirement	**QL** – Quantity Limit	**YQ** – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	**ER** – Early Refill	**RX** – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS
Aetna Better Health of Louisiana **1-855-242-0802**
AmeriHealth Caritas Louisiana **1-800-684-5502**
Fee-for-Service (FFS) Louisiana Legacy Medicaid **1-866-730-4357**
Healthy Blue **1-844-521-6942**
Louisiana Healthcare Connections **1-888-929-3790**
UnitedHealthcare **1-800-310-6826**

Anticonvulsants

POS Edits
AL – Fycompa® (perampanel) is limited to use in recipients who are at least 4 years old. *The age limit may be overridden at the pharmacy POS after the dispensing pharmacist consults with the prescriber to verify necessity of prescribing perampanel for a child younger than 4 years of age.*
BH – Additional behavioral-health related clinical information (trial of behavioral therapy, etc.) is required for carbamazepine and clonazepam when requested for a behavioral health diagnosis for recipients who are younger than 7 years of age.
BY – Pharmacy claims for selected anxiolytics, when submitted with a seizure-related diagnosis code will bypass the behavioral-health clinical authorization requirement, the restriction on concurrent use with opioids, and quantity limits (see Anticonvulsant Quantity Limits *with* Bypass Diagnosis Codes chart below).
CU – Benzodiazepines are monitored at POS for concurrent use with opioids and buprenorphine-containing products. - Concurrent pharmacy claims for benzodiazepines and buprenorphine will deny. - Incoming benzodiazepine pharmacy claims will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for an opioid.
PU – For Epidiolex®, the pharmacy POS system verifies that there has been a paid claim in the previous 365 days for **AT LEAST TWO** of the following agents [brand/generic or preferred/non-preferred]: - Clobazam - Felbamate - Lamotrigine - Levetiracetam - Rufinamide - Topiramate - Valproate derivatives

QL – Solid oral dosage forms of clonazepam have a quantity limit when used for a non-seizure-related diagnosis. Pharmacy claims for clonazepam that are submitted with a seizure-related diagnosis will bypass the quantity limit.	**Anticonvulsant Quantity Limits *with* Bypass Diagnosis Codes**		
	Generic (Brand Example)	**Quantity Limit**	
	Clonazepam (Klonopin®)	90 units in 30 days	
	Seizure-Related Diagnosis Codes **Will** Bypass Behavioral Health Clinical Authorization Requirement **or** Concurrent Use with Opioids **or** Applicable Quantity Limits	Epilepsy, Seizures	G40.*
		Convulsions in Newborn	P90
		Other Convulsions	R56.*

TD – Clonazepam is monitored at the pharmacy POS for duplication of therapy with other benzodiazepines and with oxybate (Xyrem®).

Revision / Date	Implementation Date
Created POS Document	November 2020
Added previous-use requirement for Epidiolex® / December 2020	April 2021